“…35,36 Similar findings have been seen in the midostaurin studies 44,45 and other reports. 47,48 Our treatment approach The first step is to identify whether the AMN component takes priority over the SM component of the disease for treatment purposes. High-grade AMN's, including AML, high-/very high-risk MDS or CMML, or those with >10% BM blasts, likely take precedence in this regard; however, we take into account multiple factors, including patient symptoms, pattern of organomegaly/organopathy, BM MC burden, KITD816V VAF, next-generation sequencing mutational profile, as well as patient performance status and comorbidities, before finalizing a treatment plan.…”